Fountainhead Global Partners provides 360-degree strategic advice on China — led by a principal with 25 years of legal, political, and commercial experience across China and Hong Kong, and supported by a team of specialists spanning technology, supply chain, regulatory, and national security.
"China risk does not sit neatly within a single discipline. Neither should the advice."
Fountainhead Global Partners delivers 360-degree strategic advice on China to life sciences corporations, pharmaceutical and biotechnology firms, financial institutions, and investment funds. Our work spans the full spectrum of China risk — political, commercial, technical, and geopolitical — because our clients' decisions rarely sit neatly within a single discipline.
We are led by a principal with 25 years of experience in legal disputes and political engagement across China and Hong Kong — one of the deepest individual track records available in the market. Around that anchor, we have assembled a team of China specialists whose expertise spans technology, supply chain, national security, and regulatory, enabling us to advise on complex, multi-dimensional China questions from a single point of contact.
Our two primary client verticals are life sciences and pharmaceutical — where China's innovation pipeline and regulatory architecture create complexity that generalist advisers cannot navigate — and financial institutions, where banks, private equity, and hedge funds face an expanding set of China-related counterparty, investment, and regulatory questions that their internal teams are rarely equipped to answer with primary-source rigour.
Every Fountainhead capability begins with Chinese-language primary sources. The analysis, legal interpretation, and strategic advice that follow are built on intelligence that clients cannot obtain anywhere else.
Institutional analysis of Chinese pharmaceutical and biotechnology entities — state ownership mapping, patent co-inventor audits, research institution affiliation screening — from primary sources, in Chinese.
Pre-transaction analysis of Chinese counterparties for licensing, M&A, and joint venture transactions — covering ownership structures, state relationships, and regulatory risk invisible to English-language advisers.
Real-time monitoring of Chinese clinical trial registries, regulatory approvals, patent filings, corporate announcements, and deal activity — translated into competitive and investment intelligence for US and European pharmaceutical companies and financial institutions.
Systematic review of Chinese suppliers and service relationships within pharmaceutical supply chains — identifying state ownership structures, national security regulatory exposure, and transition requirements.
Scenario analysis and decision-grade briefings on China's regulatory trajectory, technology and supply chain strategy, and the political system factors that shape commercial outcomes — for boards and investment committees.
Senior advisory sessions combining PRC legal authority and sector expertise — designed for boards, C-suites, investment committees, and credit and risk committees at financial institutions requiring authoritative China assessment on a specific decision or transaction.
Every Fountainhead engagement produces a named deliverable with a defined scope, timeline, and fee. No ambiguity about what you are commissioning or what you will receive.
Every major consultancy advising on China risk is working from English-language sources. We are not. That is the entire difference.
Engagements begin with a confidential conversation. Tell us the decision you are facing — we will tell you whether Fountainhead can help and on what timeline.